[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Cancer/Tumor Profiling Market by Technology (Immunoassay, NGS, PCR, In Situ Hybridization), Cancer Type (Breast, Lung, Colorectal), Biomarker Type (Genomic Biomarkers, Protein Biomarkers), Application (Diagnostics, Prognostics) - Global Forecast to 2024

June 2019 | 224 pages | ID: C3700EC2C05EN
MarketsandMarkets

US$ 5,650.00

E-mail Delivery (PDF)

Download PDF Leaflet

Wire Transfer
Checkout Later
Need Help? Ask a Question
“Cancer/tumor profiling market is projected to grow at a CAGR of 10.5% during the forecast period (2019–2024).”

Cancer/tumor profiling market is projected to reach USD 12.4 billion by 2024 from USD 7.5 billion in 2019, at a CAGR of 10.5%. The increasing incidence of cancer across the globe and the rising use of biomarkers in tumor profiling are the primary growth drivers for this market. Additionally, the increase in cancer research & funding initiatives and technological advancements in profiling technologies are also propelling the growth of the cancer/tumor profiling market.

The increasing demand for personalized medicine and the growing need for point-of-care diagnostics is expected to offer significant growth opportunities for market players during the forecast period. On the other hand, the high capital investment required for biomarker discovery and the technical issues with sample collection and storage are the key factors restraining the market growth.

“The next-generation sequencing (NGS) segment is expected to grow at the highest rate during the forecast period.”

Based on technology, cancer/tumor profiling market has been segmented into immunoassays, in-situ hybridization, next-generation sequencing (NGS), polymerase chain reaction (PCR), mass spectrometry, microarrays, and other technologies. The next-generation sequencing (NGS) segment is projected to witness the highest growth in cancer/tumor profiling market during the forecast period. The benefits of effectively exploring genetic alterations in a wide range of cancers and the identification of a number of differentially expressed genes & genetic/epigenetic variants as potential targets aid in the development of new biomarkers for early diagnosis of the disease. These factors are supporting the adoption of NGS technology in cancer/tumor profiling market.

“The lung cancer segment is expected to grow at the highest CAGR during the forecast period.”

Based on cancer type, the market is segmented into breast cancer, lung cancer, colorectal cancer, prostate cancer, melanoma, and other cancers. The lung cancer segment is expected to register the highest CAGR during the forecast period. The increasing incidence of lung cancer worldwide and the growing need for early diagnosis are supporting the growth of this segment.

“The protein biomarkers segment is expected to grow at the highest CAGR during the forecast period.”

Based on biomarker type, cancer/tumor profiling market is segmented into genetic biomarkers, protein biomarkers, and other biomarkers. The protein biomarkers segment is estimated to grow at the highest CAGR during the forecast period majorly due to the increasing adoption of proteomic methods for biomarker research to improve the drug development process. They also showcase an enormous potential for directing personalized cancer therapy and treatment monitoring.

“The clinical applications segment is expected to grow at the highest rate during the forecast period.”

Based on applications, cancer/tumor profiling market is segmented into research and clinical applications. The research applications segment is further sub-segmented into biomarker discovery and personalized medicine. On the other hand, the clinical applications segment is sub-segmented into diagnostics, prognostics, screening, and monitoring & treatment.

The clinical applications segment is expected to grow at the highest CAGR during the forecast period. With the increasing incidence rate of cancers across the globe and the rising availability of molecular profiling, and functional assessment of signaling pathways of advanced solid tumors, the use of tumor profiling techniques is gaining momentum for clinical practice.

“APAC is projected to witness the highest growth during the forecast period.”

Although North America is expected to account for the largest share of global cancer/tumor profiling market in 2018, APAC is expected to witness the highest CAGR during the forecast period. This is primarily due to the high incidence of cancer, growing proteomics & genomics research, rising research funding, increasing investments by pharmaceutical & biotechnology companies, and growing awareness about personalized therapeutics.

A breakdown of the primary participants referred to for this report is provided below:
  • By Company Type: Tier 1–35%, Tier 2–45%, and Tier 3–20%
  • By Designation: C-level–35%, Director-level–25%, and Others–40%
  • By Region: North America–45%, Europe–30%, Asia Pacific–20%, Rest of the World-5%
The prominent players in cancer/tumor profiling market are Illumina, Inc. (US), QIAGEN N.V. (Germany), NeoGenomics Laboratories, Inc. (US), HTG Molecular Diagnostics, Inc. (US), Genomic Health Inc. (US), Caris Life Sciences (US), Helomics Corporation (US), NanoString Technologies, Inc. (US), Sysmex Corporation (Japan), Ribomed Biotechnologies, Inc. (US), Guardant Health, Inc. (US), and Foundation Medicine (US).

Research Coverage:

The report analyzes the market for various cancer/tumor profiling technologies and their adoption pattern. It aims at estimating the market size and future growth potential of cancer/tumor profiling market and the different segments such as by technology, cancer type, biomarker type, and application. The report also includes an in-depth competitive analysis of the key players in this market, along with their company profiles, product offerings, and recent developments.

Reasons to Buy the Report

The report will enrich established firms as well as new entrants/smaller firms to gauge the pulse of the market, which, in turn, would help them to garner a more significant share. Firms purchasing the report could use one, or a combination of the below mentioned five strategies for strengthening their market presence.

This report provides insights on the following pointers:
  • Market Penetration: Comprehensive information on the product portfolios offered by the top players in cancer/tumor profiling market.
  • Product Development/Innovation: Detailed insights on the upcoming trends, R&D activities, and product launches in cancer/tumor profiling market.
  • Market Development: Comprehensive information on lucrative emerging regions.
  • Market Diversification: Exhaustive information about new products, growing geographies, and recent developments in global cancer/tumor profiling market.
  • Competitive Assessment: In-depth assessment of market segments, growth strategies, revenue analysis, and products of the leading players in cancer/tumor profiling market.
1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 MARKET SCOPE
    1.3.1.1 Markets covered
    1.3.1.2 Years considered for the study
1.4 CURRENCY
1.5 STAKEHOLDERS
1.6 LIMITATIONS

2 RESEARCH METHODOLOGY

2.1 RESEARCH APPROACH
  2.1.1 SECONDARY RESEARCH
    2.1.1.1 Key data from secondary sources
  2.1.2 PRIMARY RESEARCH
    2.1.2.1 Key data from primary sources
    2.1.2.2 Breakdown of primaries
    2.1.2.3 Key industry insights
2.2 MARKET SIZE ESTIMATION
2.3 DATA TRIANGULATION APPROACH
2.4 ASSUMPTIONS FOR THE STUDY

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

4.1 CANCER/TUMOR PROFILING: MARKET OVERVIEW
4.2 CANCER/TUMOR PROFILING MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
4.3 REGIONAL MIX: CANCER/TUMOR PROFILING MARKET (2019–2024)
4.4 CANCER/TUMOR PROFILING MARKET: DEVELOPED VS. DEVELOPING MARKETS (2019 VS. 2024)

5 MARKET OVERVIEW

5.1 INTRODUCTION
5.2 MARKET DYNAMICS
  5.2.1 MARKET DRIVERS
    5.2.1.1 Increasing incidence of cancer
    5.2.1.2 Increasing use of biomarkers in cancer profiling
    5.2.1.3 Increasing cancer research and funding
    5.2.1.4 Technological advancements
  5.2.2 MARKET RESTRAINTS
    5.2.2.1 High capital investment
    5.2.2.2 Technical issues with sample collection and storage
  5.2.3 MARKET OPPORTUNITIES
    5.2.3.1 Increasing demand for personalized medicine
    5.2.3.2 Growing need for point-of-care diagnostics
  5.2.4 MARKET CHALLENGES
    5.2.4.1 Low biomarker discovery-to-approval ratio
    5.2.4.2 Poor regulatory and reimbursement scenario

6 INDUSTRY INSIGHTS

6.1 INTRODUCTION
6.2 INDUSTRY TRENDS
  6.2.1 INTEGRATION OF OMICS DATA
  6.2.2 ADVANCES IN LIQUID BIOPSY
  6.2.3 ORGANOIDS FOR PERSONALIZED MEDICINE

7 CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY

7.1 INTRODUCTION
7.2 IMMUNOASSAYS
  7.2.1 IMMUNOASSAY TESTS IDENTIFY AND ASSESS THE PROGRESSION OF DISEASE, THEREBY PROVIDING INFORMATION VITAL FOR BETTER THERAPEUTIC CHOICES
7.3 NEXT-GENERATION SEQUENCING
  7.3.1 ADVANCES IN NGS MULTIPLEXING CAPABILITIES ENABLE ONE ASSAY TO PROVIDE A COMPLETE TUMOR MOLECULAR PROFILE
7.4 POLYMERASE CHAIN REACTION
  7.4.1 REAL-TIME PCR HELPS IN THE QUANTIFICATION OF LOW-COPY TRANSCRIPTS, AIDING BIOMARKER IDENTIFICATION
7.5 IN SITU HYBRIDIZATION
  7.5.1 FISH IS THE GOLD STANDARD FOR EVALUATING SOME KEY BIOMARKERS AND PLAYS A CRITICAL ROLE IN GUIDING TARGETED THERAPIES
7.6 MICROARRAYS
  7.6.1 MICROARRAYS ARE WIDELY ADOPTED IN DIAGNOSTICS AS THEY AID IN PREDICTING THE RECURRENCE OF CANCER AFTER TREATMENT
7.7 MASS SPECTROMETRY
  7.7.1 TECHNOLOGICAL ADVANCEMENTS ARE SUPPORTING THE ADOPTION OF THIS TECHNOLOGY FOR SENSITIVE, RELIABLE, AND RAPID DIAGNOSIS
7.8 OTHER TECHNOLOGIES

8 CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE

8.1 INTRODUCTION
8.2 BREAST CANCER
  8.2.1 BREAST CANCER IS THE MOST COMMON CANCER FOUND AMONG WOMEN
8.3 LUNG CANCER
  8.3.1 MOLECULAR CHARACTERIZATION OF TUMORS USING NGS HAS IS A KEY TOOL FOR THE CLINICAL MANAGEMENT OF NSCLC PATIENTS
8.4 COLORECTAL CANCER
  8.4.1 IHC, PCR, MICROARRAYS, AND IMAGING TECHNOLOGIES ARE MAJOR TECHNOLOGIES USED IN COLORECTAL DIAGNOSTICS
8.5 PROSTATE CANCER
  8.5.1 PROSTATE-SPECIFIC ANTIGEN IS A WIDELY USED FDA-APPROVED BIOMARKER FOR PROSTATE CANCER SCREENING
8.6 MELANOMA
  8.6.1 RT-QPCR IS GENERALLY UTILIZED TO CONDUCT MOLECULAR PROFILING AND ANALYZE BIOMARKERS IN MELANOMAS
8.7 OTHER CANCERS

9 CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE

9.1 INTRODUCTION
9.2 GENETIC BIOMARKERS
  9.2.1 GENETIC BIOMARKERS ARE FREQUENTLY USED IN CLINICAL PRACTICE FOR DIAGNOSIS AND PROGNOSIS
9.3 PROTEIN BIOMARKERS
  9.3.1 PROTEOMIC METHODS SHOWCASE SIGNIFICANT PROMISE FOR THE DISCOVERY OF NOVEL BIOMARKERS
9.4 OTHER BIOMARKERS

10 CANCER/TUMOR PROFILING MARKET, BY APPLICATION

10.1 INTRODUCTION
10.2 RESEARCH APPLICATIONS
  10.2.1 BIOMARKER DISCOVERY
    10.2.1.1 Biomarkers are being exploited for the development of personalized or precision medicine
  10.2.2 PERSONALIZED MEDICINE
    10.2.2.1 The field of personalized medicine is witnessing rapid growth in the area of oncology
10.3 CLINICAL APPLICATIONS
  10.3.1 DIAGNOSTICS
    10.3.1.1 Tumor profiling is rapidly gaining momentum in the area of diagnostics
  10.3.2 PROGNOSTICS
    10.3.2.1 Advancements in molecular biology are aiding the uptake of tumor profiling in this segment
  10.3.3 MONITORING & TREATMENT
    10.3.3.1 Multiplatform profiling analyses are gaining recognition for monitoring and treatment among cancer patients
  10.3.4 SCREENING
    10.3.4.1 Screening tests help in deciding if diagnostic tests are required by the patient

11 CANCER/TUMOR PROFILING MARKET, BY REGION

11.1 INTRODUCTION
11.2 NORTH AMERICA
  11.2.1 US
    11.2.1.1 US dominates the North American cancer/tumor profiling market
  11.2.2 CANADA
    11.2.2.1 Growing public-private partnerships to promote proteomics research are expected to drive the market in Canada
11.3 EUROPE
  11.3.1 GERMANY
    11.3.1.1 Advancements proteomics and genomics research are expected to drive market growth
  11.3.2 UK
    11.3.2.1 Growth in the life science industry and the increase in academia-industry partnerships will be the key factors driving the market
  11.3.3 FRANCE
    11.3.3.1 Growth in this market is primarily driven by increasing investments in life science R&D for infrastructural development
  11.3.4 ITALY
    11.3.4.1 Increasing investment in cancer and translational research is expected to propel market growth during the forecast period
  11.3.5 SPAIN
    11.3.5.1 Rising incidence of cancer and increasing focus on cancer biomarkers by various medical societies to support market growth in Spain
  11.3.6 REST OF EUROPE
11.4 ASIA PACIFIC
  11.4.1 JAPAN
    11.4.1.1 Large number of research initiatives towards the development of precision medicine supporting market growth in Japan
  11.4.2 CHINA
    11.4.2.1 China has the fastest-growing research sector in the APAC region
  11.4.3 INDIA
    11.4.3.1 Increasing pharma R&D and government funding in the biotechnology industry are the major factors driving market growth in India
  11.4.4 REST OF ASIA PACIFIC
11.5 LATIN AMERICA
  11.5.1 GROWING PROTEOMICS RESEARCH IN THE FIELD OF CANCER ALONG WITH THE RISING USE OF ADVANCED TECHNIQUES TO DRIVE MARKET GROWTH
11.6 MIDDLE EAST & AFRICA
  11.6.1 GROWING GENOMICS AND PROTEOMICS RESEARCH AND INCREASING RESEARCH COLLABORATIONS ARE EXPECTED TO SUPPORT MARKET GROWTH

12 COMPETITIVE LANDSCAPE

12.1 OVERVIEW
12.2 COMPETITIVE LEADERSHIP MAPPING
  12.2.1 VISIONARY LEADERS
  12.2.2 INNOVATORS
  12.2.3 DYNAMIC DIFFERENTIATORS
  12.2.4 EMERGING COMPANIES
12.3 COMPETITIVE SITUATION AND TRENDS
  12.3.1 PRODUCT LAUNCHES, APPROVALS, AND ENHANCEMENTS
  12.3.2 EXPANSIONS
  12.3.3 ACQUISITIONS
  12.3.4 OTHER STRATEGIES

13 COMPANY PROFILES

(Business Overview, Products Offered, Recent Developments, SWOT Analysis, MnM View)*
13.1 ILLUMINA, INC.
13.2 QIAGEN N.V.
13.3 NEOGENOMIC LABORATORIES, INC.
13.4 SYSMEX CORPORATION
13.5 HTG MOLECULAR DIAGNOSTICS, INC.
13.6 HELOMICS CORPORATION
13.7 GENOMIC HEALTH, INC.
13.8 CARIS LIFE SCIENCES
13.9 NANOSTRING TECHNOLOGIES, INC.
13.10 RIBOMED BIOTECHNOLOGIES, INC.
13.11 GUARDANT HEALTH, INC.
13.12 FOUNDATION MEDICINE
*Business Overview, Products Offered, Recent Developments, SWOT Analysis, MnM View might not be captured in case of unlisted companies.

14 APPENDIX

14.1 INSIGHTS OF INDUSTRY EXPERTS
14.2 MARKET SIZING & VALIDATION APPROACH
14.3 DISCUSSION GUIDE
14.4 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
14.5 AVAILABLE CUSTOMIZATIONS
14.6 RELATED REPORTS
14.7 AUTHOR DETAILS

LIST OF TABLES

TABLE 1 MARKET DRIVERS: IMPACT ANALYSIS
TABLE 2 MARKET RESTRAINTS: IMPACT ANALYSIS
TABLE 3 MARKET OPPORTUNITIES: IMPACT ANALYSIS
TABLE 4 MARKET CHALLENGES: IMPACT ANALYSIS
TABLE 5 CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2017–2024 (USD MILLION)
TABLE 6 CANCER/TUMOR PROFILING MARKET FOR IMMUNOASSAYS, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 7 CANCER/TUMOR PROFILING MARKET FOR NEXT-GENERATION SEQUENCING, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 8 CANCER/TUMOR PROFILING MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 9 CANCER/TUMOR PROFILING MARKET FOR IN SITU HYBRIDIZATION, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 10 CANCER/TUMOR PROFILING MARKET FOR MICROARRAYS, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 11 CANCER/TUMOR PROFILING MARKET FOR MASS SPECTROMETRY, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 12 CANCER/TUMOR PROFILING MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 13 CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2017–2024 (USD MILLION)
TABLE 14 CANCER/TUMOR PROFILING MARKET FOR BREAST CANCER, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 15 CANCER/TUMOR PROFILING MARKET FOR LUNG CANCER, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 16 CANCER/TUMOR PROFILING MARKET FOR COLORECTAL CANCER, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 17 CANCER/TUMOR PROFILING MARKET FOR PROSTATE CANCER, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 18 CANCER/TUMOR PROFILING MARKET FOR MELANOMA, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 19 CANCER/TUMOR PROFILING MARKET FOR OTHER CANCERS, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 20 CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2017–2024 (USD MILLION)
TABLE 21 CANCER/TUMOR PROFILING MARKET FOR GENETIC BIOMARKERS, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 22 CANCER/TUMOR PROFILING MARKET FOR PROTEIN BIOMARKERS, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 23 CANCER/TUMOR PROFILING MARKET FOR OTHER BIOMARKERS, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 24 CANCER/TUMOR PROFILING MARKET, BY APPLICATION, 2017–2024 (USD MILLION)
TABLE 25 CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2017–2024 (USD MILLION)
TABLE 26 CANCER/TUMOR PROFILING MARKET FOR BIOMARKER DISCOVERY, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 27 CANCER/TUMOR PROFILING MARKET FOR PERSONALIZED MEDICINE, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 28 CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2017–2024 (USD MILLION)
TABLE 29 CANCER/TUMOR PROFILING MARKET FOR DIAGNOSTICS, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 30 CANCER/TUMOR PROFILING MARKET FOR PROGNOSTICS, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 31 CANCER/TUMOR PROFILING MARKET FOR MONITORING & TREATMENT, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 32 CANCER/TUMOR PROFILING MARKET FOR SCREENING, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 33 CANCER/TUMOR PROFILING MARKET, BY REGION, 2017–2024 (USD MILLION)
TABLE 34 NORTH AMERICA: CANCER/TUMOR PROFILING MARKET, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 35 NORTH AMERICA: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2017–2024 (USD MILLION)
TABLE 36 NORTH AMERICA: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2017–2024 (USD MILLION)
TABLE 37 NORTH AMERICA: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2017–2024 (USD MILLION)
TABLE 38 NORTH AMERICA: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2017–2024 (USD MILLION)
TABLE 39 NORTH AMERICA: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2017–2024 (USD MILLION)
TABLE 40 US: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2017–2024 (USD MILLION)
TABLE 41 US: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2017–2024 (USD MILLION)
TABLE 42 US: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2017–2024 (USD MILLION)
TABLE 43 US: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2017–2024 (USD MILLION)
TABLE 44 US: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2017–2024 (USD MILLION)
TABLE 45 CANADA: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2017–2024 (USD MILLION)
TABLE 46 CANADA: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2017–2024 (USD MILLION)
TABLE 47 CANADA: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2017–2024 (USD MILLION)
TABLE 48 CANADA: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2017–2024 (USD MILLION)
TABLE 49 CANADA: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2017–2024 (USD MILLION)
TABLE 50 EUROPE: CANCER/TUMOR PROFILING MARKET, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 51 EUROPE: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2017–2024 (USD MILLION)
TABLE 52 EUROPE: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2017–2024 (USD MILLION)
TABLE 53 EUROPE: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2017–2024 (USD MILLION)
TABLE 54 EUROPE: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2017–2024 (USD MILLION)
TABLE 55 EUROPE: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2017–2024 (USD MILLION)
TABLE 56 GERMANY: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2017–2024 (USD MILLION)
TABLE 57 GERMANY: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2017–2024 (USD MILLION)
TABLE 58 GERMANY: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2017–2024 (USD MILLION)
TABLE 59 GERMANY: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2017–2024 (USD MILLION)
TABLE 60 GERMANY: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2017–2024 (USD MILLION)
TABLE 61 UK: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2017–2024 (USD MILLION)
TABLE 62 UK: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2017–2024 (USD MILLION)
TABLE 63 UK: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2017–2024 (USD MILLION)
TABLE 64 UK: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2017–2024 (USD MILLION)
TABLE 65 UK: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2017–2024 (USD MILLION)
TABLE 66 FRANCE: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2017–2024 (USD MILLION)
TABLE 67 FRANCE: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2017–2024 (USD MILLION)
TABLE 68 FRANCE: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2017–2024 (USD MILLION)
TABLE 69 FRANCE: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2017–2024 (USD MILLION)
TABLE 70 FRANCE: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2017–2024 (USD MILLION)
TABLE 71 ITALY: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2017–2024 (USD MILLION)
TABLE 72 ITALY: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2017–2024 (USD MILLION)
TABLE 73 ITALY: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2017–2024 (USD MILLION)
TABLE 74 ITALY: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2017–2024 (USD MILLION)
TABLE 75 ITALY: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2017–2024 (USD MILLION)
TABLE 76 SPAIN: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2017–2024 (USD MILLION)
TABLE 77 SPAIN: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2017–2024 (USD MILLION)
TABLE 78 SPAIN: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2017–2024 (USD MILLION)
TABLE 79 SPAIN: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2017–2024 (USD MILLION)
TABLE 80 SPAIN: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2017–2024 (USD MILLION)
TABLE 81 ROE: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2017–2024 (USD MILLION)
TABLE 82 ROE: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2017–2024 (USD MILLION)
TABLE 83 ROE: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2017–2024 (USD MILLION)
TABLE 84 ROE: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2017–2024 (USD MILLION)
TABLE 85 ROE: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2017–2024 (USD MILLION)
TABLE 86 ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 87 ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2017–2024 (USD MILLION)
TABLE 88 ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2017–2024 (USD MILLION)
TABLE 89 ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2017–2024 (USD MILLION)
TABLE 90 ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2017–2024 (USD MILLION)
TABLE 91 ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2017–2024 (USD MILLION)
TABLE 92 JAPAN: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2017–2024 (USD MILLION)
TABLE 93 JAPAN: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2017–2024 (USD MILLION)
TABLE 94 JAPAN: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2017–2024 (USD MILLION)
TABLE 95 JAPAN: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2017–2024 (USD MILLION)
TABLE 96 JAPAN: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2017–2024 (USD MILLION)
TABLE 97 CHINA: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2017–2024 (USD MILLION)
TABLE 98 CHINA: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2017–2024 (USD MILLION)
TABLE 99 CHINA: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2017–2024 (USD MILLION)
TABLE 100 CHINA: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2017–2024 (USD MILLION)
TABLE 101 CHINA: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2017–2024 (USD MILLION)
TABLE 102 INDIA: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2017–2024 (USD MILLION)
TABLE 103 INDIA: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2017–2024 (USD MILLION)
TABLE 104 INDIA: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2017–2024 (USD MILLION)
TABLE 105 INDIA: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2017–2024 (USD MILLION)
TABLE 106 INDIA: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2017–2024 (USD MILLION)
TABLE 107 ROAPAC: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2017–2024 (USD MILLION)
TABLE 108 ROAPAC: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2017–2024 (USD MILLION)
TABLE 109 ROAPAC: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2017–2024 (USD MILLION)
TABLE 110 ROAPAC: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2017–2024 (USD MILLION)
TABLE 111 ROAPAC: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2017–2024 (USD MILLION)
TABLE 112 LATIN AMERICA: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2017–2024 (USD MILLION)
TABLE 113 LATIN AMERICA: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2017–2024 (USD MILLION)
TABLE 114 LATIN AMERICA: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2017–2024 (USD MILLION)
TABLE 115 LATIN AMERICA: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2017–2024 (USD MILLION)
TABLE 116 LATIN AMERICA: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2017–2024 (USD MILLION)
TABLE 117 MIDDLE EAST & AFRICA: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2017–2024 (USD MILLION)
TABLE 118 MIDDLE EAST & AFRICA: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2017–2024 (USD MILLION)
TABLE 119 MIDDLE EAST & AFRICA: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2017–2024 (USD MILLION)
TABLE 120 MIDDLE EAST & AFRICA: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2017–2024 (USD MILLION)
TABLE 121 MIDDLE EAST & AFRICA: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2017–2024 (USD MILLION)

LIST OF FIGURES

FIGURE 1 CANCER/TUMOR PROFILING MARKET
FIGURE 2 RESEARCH DESIGN
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATIONS, AND REGION
FIGURE 4 BOTTOM-UP APPROACH
FIGURE 5 TOP-DOWN APPROACH
FIGURE 6 DATA TRIANGULATION METHODOLOGY
FIGURE 7 CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2019 VS. 2024 (USD MILLION)
FIGURE 8 CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2019 VS. 2024 (USD MILLION)
FIGURE 9 CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2019 VS. 2024 (USD MILLION)
FIGURE 10 CANCER/TUMOR PROFILING MARKET, BY APPLICATION, 2019 VS. 2024 (USD MILLION)
FIGURE 11 GEOGRAPHICAL SNAPSHOT OF THE CANCER/TUMOR PROFILING MARKET
FIGURE 12 INCREASING DEMAND FOR PERSONALIZED MEDICINE TO DRIVE MARKET GROWTH
FIGURE 13 CHINA TO REGISTER THE HIGHEST GROWTH IN THE CANCER/TUMOR PROFILING MARKET DURING THE FORECAST PERIOD
FIGURE 14 APAC TO WITNESS THE HIGHEST GROWTH DURING THE FORECAST
PERIOD (2019–2024)
FIGURE 15 DEVELOPING MARKETS TO REGISTER A HIGHER GROWTH RATE BETWEEN

2019 & 2024

FIGURE 16 CANCER/TUMOR PROFILING MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
FIGURE 17 GLOBAL CANCER INCIDENCE, 2008–2030
FIGURE 18 LAUNCH OF PERSONALIZED MEDICINE PRODUCTS, 2008–2016
FIGURE 19 INCREASING USE OF INTEGRATED OMICS DATA AND GROWING FOCUS ON LIQUID BIOPSY TESTS ARE KEY MARKET TRENDS
FIGURE 20 IMMUNOASSAYS TO DOMINATE THE CANCER/TUMOR PROFILING MARKET DURING THE FORECAST PERIOD
FIGURE 21 BREAST CANCER SEGMENT TO DOMINATE THE CANCER/TUMOR PROFILING MARKET DURING THE FORECAST PERIOD
FIGURE 22 GLOBAL LUNG CANCER INCIDENCE, 2012-2030
FIGURE 23 COLORECTAL CANCER INCIDENCE RATE, KEY COUNTRIES (2018)
FIGURE 24 GENETIC BIOMARKERS TO DOMINATE THE CANCER/TUMOR PROFILING MARKET DURING THE FORECAST PERIOD
FIGURE 25 RESEARCH APPLICATIONS TO DOMINATE THE CANCER/TUMOR PROFILING MARKET DURING THE FORECAST PERIOD
FIGURE 26 CANCER/TUMOR PROFILING MARKET: GEOGRAPHIC SNAPSHOT (2018)
FIGURE 27 NORTH AMERICA: CANCER/TUMOR PROFILING MARKET SNAPSHOT
FIGURE 28 EUROPE: CANCER/TUMOR PROFILING MARKET SNAPSHOT
FIGURE 29 ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET SNAPSHOT
FIGURE 30 ILLUMINA, INC.: COMPANY SNAPSHOT (2018)
FIGURE 31 QIAGEN N.V.: COMPANY SNAPSHOT (2018)
FIGURE 32 NEOGENOMIC LABORATORIES, INC.: COMPANY SNAPSHOT (2018)
FIGURE 33 SYSMEX CORPORATION: COMPANY SNAPSHOT (2018)
FIGURE 34 HTG MOLECULAR DIAGNOSTICS, INC.: COMPANY SNAPSHOT (2018)
FIGURE 35 GENOMIC HEALTH, INC.: COMPANY SNAPSHOT (2018)
FIGURE 36 NANOSTRING TECHNOLOGIES, INC.: COMPANY SNAPSHOT (2018)
FIGURE 37 GUARDANT HEALTH, INC.: COMPANY SNAPSHOT (2018)
FIGURE 38 FOUNDATION MEDICINE: COMPANY SNAPSHOT (2018)


More Publications